Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells

Biomedicine and Pharmacotherapy

Volumn 68, Issue 2, 2014, Pages 179-183

  Mao, Zonglei ^a   Zhou, Jin ^a   Luan, Junwei ^c   Sheng, Weihua ^b   Shen, Xiaochun ^a   Dong, Xiaoqiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c First Hospital of Zibo   (China)

Author keywords

Multidrug resistance; PI3K Akt; Tamoxifen

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHODAMINE 123; TAMOXIFEN;

ARTICLE; CANCER CELL; CELL COUNTING; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; STOMACH CANCER; WESTERN BLOTTING;

MULTIDRUG RESISTANCE; PI3K/AKT; TAMOXIFEN;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TAMOXIFEN;

EID: 84897092972     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.10.003     Document Type: Article

References (29)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistical. CA Cancer J Clin 2011, 61:69-90.
2. Szakacs G., paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
3. Xia L., Zhang D., Du R., Pan Y., Zhao L., Sun S., et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL-2 in human gastric cancer cell. Int J Cancer 2008, 123:372-379.
4. O'Connor The pharmacology of cancer resistance. Anticancer Res 2007, 27:1267-1272.
5. Nakayama Y., Sakamoto H., Satoh K., Yamamoto T. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase. Survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett 2000, 161:63-71.
6. Guo R., Huang Z., Shu Y., Jin S., Ge H. Tamoxifen inhibits proliferation and induces apoptosis in human hepatocellular carcinoma cell line HepG2 via down-regulation of survivin expression. Biomed Pharmacother 2009, 63:375-379.
7. Shen L.Z., Hua Y.B., Yu X.M., Xu Q., Chen T., Wang J.H., et al. Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo. World J Gastroenterol 2005, 11:1060-1064.
8. Hotta T., Tanimura H., Yamaue H., Iwahashi M., Tani M., Tsunoda T., et al. Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells. J Surg Res 1996, 66:31-35.
9. Liu Z.H., Ma Y.L., He Y.P., Zhang P., Zhou Y.K., Qin H. Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics. Mol Biol Rep 2011, 38:1769-1775.
10. Kennedy S.G., Wagner A.J., Conzen S.D., Jordan J., Bellacosa A., Tsichlis P.N., et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997, 11:701-713.
11. Lawlor M.A., Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses. J Cell Sci 2001, 114:2903-2910.
12. Michl P., Downward J. Mechanisms of disease: PI3K/Akt signaling in gastrointestinal cancers. Z Gastroenterol 2005, 43:1133-1139.
13. Han Z., Hong L., Han Y., Wu K., Han S., Shen H., et al. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res 2007, 26:261-268.
14. Barancik M., Bohacova V., Sedlak J., Sulova Z., Breier A. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 2006, 29:426-434.
15. Oki E., Baba H., Tokunaga E., Nakamura T., Ueda N., Futatsuqi M., et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005, 117:376-380.
16. Zheng T., Wang J., Chen X., Liu L.X. Role of microRNA in anticancer drug resistance. Int J Cancer 2009, 126:2-10.
17. Skvortsova I., Skvortsov S., Haidenberger A., Devries A., Nevinny-Stickel M., Saurer M., et al. Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. J Chemother 2004, 16:372-380.
18. Liu L., Ning X., Sun L., Zhang H., Shi Y., Guo C., et al. Hypoxia-inducible factor-1α contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 2008, 99:121-128.
19. Sui H., Fan Z.Z., Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res 2012, 40:426-435.
20. Li X., Li J.P., Yuan H.Y., Gao X., Qu X.J., Xu W.F., et al. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms. Methods Find Exp Clin Pharmacol 2007, 29:607-617.
21. Zhang Y., Qu X., Hu X., Yang X., Hou K., Teng Y., et al. Reversal of P-glycoprotein-mediated multi-drug resistance by E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J Pathol 2009, 218:248-255.
22. Goldenberg G.J., Froese E.K. Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vivo. Cancer Res 1982, 42:5147-5151.
23. Gelmann E.P. Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog. J Natl Cancer Inst 1996, 88:224-226.
24. Feng Y., Huang J., Ding Y., Xie F., Shen X. Tamoxifen-induced apoptosis of rat C6 glioma cells via PI3K/Akt, JNK and ERK activation. Oncol Rep 2010, 24:1561-1567.
25. Lam L., Hu X., Aktary Z., Andrews D.W., Pasdar M. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERα. Breast Cancer Res Treat 2009, 118:605-621.
26. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455:152-162.
27. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human 'MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 1987, 84:3004-3008.
28. Kato J., Matsushime H., Hiebert S.W., Ewen M.E., Sherr C.J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993, 7:331-342.
29. Kim J.K., Diehl J.A. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009, 220:292-296.